Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
good timing because I just doubled my position in the .14's
never done unless a warrant is attached
JJJEEEEEEEZZZZ
Could not find exhibit 1 with the $ number....from Article VI
------------------------
Consideration. In consideration of the rights granted to ALFASIGMA hereunder, ALFASIGMA shall pay to IPI the following amounts, subject to the terms and conditions of this Agreement:
(a) Initial Payment. ALFASIGMA shall pay to IPI a one-time, non-refundable, non-creditable initial payment in the amount set forth on Exhibit I (“Initial Payment”) on the Effective Date;
(b) Milestone Payments. ALFASIGMA shall pay to IPI the following one-time, non-refundable, non-creditable milestone payments (each, a “Milestone Payment”), following the occurrence of certain milestone events as set forth below (each, a “Milestone Event”).
(i) Development Milestones
For the UP/UPS Indication:
(1) US$ 1 million, upon Commencement of the First Phase III Clinical Trial; and
(2) US$ 1 million, upon the first filing of the Marketing Approval application to the US Regulatory Authority (“FDA”) or the EU Regulatory Authority (“EMA”), as applicable, without any duplication;
(ii) Regulatory Milestones
For the UP/UPS Indication:
(1) US$ 3 million, upon obtainment of the Marketing Approval from FDA; and
(2) US$ 1 million, upon obtainment of the Marketing Approval from EMA
etc
why would they want to buy shares at above the market price?
It will indeed be interesting to see how the inevitable raise is handled. I will be reading the offer for sure.
nothing wrong with lunch money...people have to eat.
I will admit that I did not think this would happen. The company has a legitimate chance to hang around now.
I wonder what the terms of the inevitable raise will be....
cheap shares were available for a while even after the PR.
Like I said earlier, this is almost infinitely better than no deal at all. It is NOT going to produce a $2 stock. It gives IPIX life, however, and perhaps some flexibility in moving forward to additional trials.
It is better than I thought they would get.
Share price should double
It is almost infinitely better than no deal.
8 minutes into the deal and stock is up 30%. where will it end up today?
under a dime next week without a bone from leo
How big will the offering be?
You were spot on with that
Any particular reason this is down 30% lately? Leo needs to pull a rabbit out of his hat....
Hahaha
yes. something is going to happen here by year-end...IND or better.
Not sure if this is the bottom but it has to be close.
$15 at year-end
In my opinion there is little if anything being done here on a day to day basis.
Unless, of course, you count "waiting for all the BP's to line up their offers"
RedHill's Talicia Could Be 'Go-To' Drug for H. Pylori -- Market Talk
DOW JONES & COMPANY, INC. 9:48 AM ET 7/12/2019
10:48 ET - RedHill Biopharma(RDHL) rises after an upgrade from WBB Securities, which thinks the Israeli company has a winner with Talicia. The FDA last week granted priority review to Talicia for treatment of Helicobacter pylori, the gut bacteria behind peptic ulcers. WBB says it expects the agency will approve Talicia based on a standard-of-care designation, which will make it the "proverbial go-to drug" for H. pylori. WBB raises RedHill to strong buy from buy and reiterates its $17 12-month price target. RedHill ADRs gain 13% to $7.50. (colin.kellaher@wsj.com)
This stock looks quite a bit weaker than I thought it would be at this point in the proceedings. I always figured fall for the topline, and the effect of the public offering has to be about over. But there has been tiny volume lately and what trading there is has been lowering the price.
we shall see...
nice summary. and exactly why I've been adding on the way up.
Yes, and daily volume is still well above average. Combine that with the upward trend and you have what looks a lot like MARKET CONFIDENCE going into the second half catalysts.
Perhaps the 15 cent trades represent capitulation.
Some folks seem to be abandoning ship...we shall see if this becomes an opportunity.
thank you
your quote "I can't imagine it would be accepted as highlighted plenary session for entire conference if data was bad IMO."
This is why I have been adding
First post on this board. Bought in on a friend's recommendation a couple months ago.
What makes this one so certain to work?
No partnering talk that I know of. Probably the main reason the prince is where it is. They have a small sales force that is underemployed right now. Talicia will get a lot of support from that group
It is pretty much as predicted. One would think they’d have a higher market cap just for being the ONE biotech that proceeds without unexplained delay
I like “not for distribution to the US....”
should be due for a flip here soon.
I agree. Have a great holiday
Up 18% in two days. Volume still light but this could be a reversal
I’m thinking August for the topline. We shall see.
Nice day for the stock. About time! Hope everyone used the drop in price productively
ProMIS Neurosciences Closing Private Placement
CANADA NEWSWIRE 6:30 AM ET 6/26/2019
/NOT FOR DISTRIBUTION TO US NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/
TORONTO, June 26, 2019 /CNW/ - ProMIS Neurosciences, Inc.(ARFXF) , a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, is pleased to announce that it is closing today a private placement of 4,680,000 units (the "Units") at a price of CDN$0.25 (or US$0.1875) per Unit (the "Offering Price") for gross proceeds of approximately CDN$1,170,000 (the "Offering").
ProMIS Neurosciences Inc. (CNW Group/ProMIS Neurosciences Inc.)
"We are pleased with the completion of this private placement", stated Dr. Elliot Goldstein, ProMIS President and CEO. "The additional funds coupled with our conservative expenditure management support a cash runway into late 2019."
Each Unit consists of one common share of the Company (each a "Share") and one share purchase warrant of the Company (each a "Warrant"). Each Warrant entitles the holder thereof to purchase one Share ("a "Warrant Share") at an exercise price of $0.35 per Warrant Share at any time for five years.
All securities issued in connection with the Offering will be subject to a four-month statutory hold period in accordance with applicable securities laws. Net proceeds from the Offering are intended to be used for working capital and general corporate purposes. Closing of the Offering is subject to TSX approval.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful. The securities issued, or to be issued, under the Offering have not been, and will not be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.
About ProMIS Neurosciences Inc.(ARFXF)
ProMIS Neurosciences, Inc. (ARFXF) is a development stage biotechnology company focused on discovering and developing antibody therapeutics selectively targeting toxic oligomers implicated in the development and progression of neurodegenerative diseases, in particular Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson's disease (PD). The Company's proprietary target discovery platform is based on the use of two complementary thermodynamic, computational discovery engines -ProMIS and Collective Coordinates – to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this unique precision approach, the Company is developing novel antibody therapeutics for AD, ALS and PD. ProMIS is headquartered in Toronto, Ontario, with offices in Cambridge, Massachusetts. ProMIS is listed on the Toronto Stock Exchange under the symbol PMN, and on the OTCQB Venture Market under the symbol ARFXF.
Visit us at www.promisneurosciences.com or follow us on Twitter and LinkedIn
The rest of this week and perhaps next week may be the low points for the share price. There is almost always some run-up to data, which in my view is still at least a month out.
true at $4...and I did take a bit off the table in the 3's.
Is it still true at $2?
May as well ride it out from here. Could go to 10 cents...could go to $10.
POOF! half the market cap is gone.